Objective To quantify vaccinations administered outside minimum and maximum recommended ages and to determine attendant costs of revaccination by analyzing immunization information system (IIS) records.
Conclusion Administration of vaccines outside recommended minimum and maximum ages is rare, reflecting a general adherence to recommendations. Error rates were higher for several vaccines, some requiring revaccination. Vaccine schedule complexity and confusion among similar products might contribute to errors. Minimization of errors reduces wastage, excess cost, and inconvenience for parents and patients. (J Pediatr 2018; 193:164-71 ).
T he US Food and Drug Administration approves vaccines for defined indications and age ranges. The Advisory Committee on Immunization Practices (ACIP) issues recommendations to guide vaccination practices in the US.
1,2 These recommendations include minimum and maximum ages and intervals for vaccination, and which age-related errors require revaccination. Over the years, the US childhood immunization schedule has increased in complexity as new vaccines have been introduced and recommendations have expanded. 1, 3, 4 For some vaccines, recommended dose volumes vary between age groups. For example, several products are available within the class of inactivated influenza vaccines. Before 2016, 1 of these products was licensed for 0.25-mL intramuscular injection in children aged 6-35 months (Fluzone Quadrivalent, Sanofi Pasteur Inc., Swiftwater, PA). This product (and other inactivated influenza vaccines) should be administered as a 0.5-mL dose to persons aged ≥36 months, and revaccination procedures are specified for scenarios in which administered vaccines or dose volumes are incorrect for a vaccinated patient. 5, 6 Introduction of new vaccines and increasing complexity of the immunization schedule increases the opportunity for vaccination errors, which potentially can leave patients less protected from vaccine-preventable diseases and generate additional costs, particularly in instances where revaccination is required. These errors waste vaccine, require additional clinical staff time and resources, and inconvenience patients and caregivers. Errors also have the potential to decrease patient confidence in the healthcare system.
Previous studies have sought to document age-related vaccination errors. During 1997, one clinic analyzed 6983 vaccine doses administered during a 3-month period to children aged <5 months and identified 4.1% of the doses as invalid, with 35.5% of patients receiving at least 1 invalid dose. 7 During 2000, it was estimated that 10.5% of a nationally representative sample of 19-to 35-month-old US children received at least 1 dose before the minimum age or minimum interval, necessitating revaccination 8 ; the national proportion of children receiving an invalid dose requiring revaccination was estimated as 8% during 2005 . 9 A more recent study analyzed vaccination errors reported to the Vaccine Adverse Event Reporting System during 2000-2013 10 and identified 5947 errors (27% of the total error reports) classified as "inappropriate vaccine schedule," indicating that vaccines had been administered outside recommended ages or with improper spacing between doses.
To provide an estimate of errors among routinely recommended vaccines in persons aged <18 years, we used providerreported vaccination records from 6 immunization information systems (IIS), quantifying the frequency of vaccination outside minimum and maximum recommended ages. IISs are confidential databases that record vaccine doses administered to persons residing within defined jurisdictions and perform a spectrum of functions that improve vaccination practices. 11 Fully functioning IISs serve providers at the time and location of clinical care by consolidating immunization histories submitted by multiple providers and supporting help to identify vaccinations that are due or that must be repeated owing to age or interval errors. Provider-reported, population-based IIS data are uniquely suited to provide comprehensive assessments of age-related vaccination errors across large populations.
Methods
During 2014, IIS sentinel sites were located in Michigan, Minnesota, North Dakota, 6 contiguous Oregon counties, Wisconsin, and New York City. Collectively, these geographic areas contain approximately 10% of the US population aged <18 years. 12 These sites receive competitive cooperative agreement funding through the Centers for Disease Control and Prevention (CDC), and all meet high IIS data quality standards, with at least 85% of persons aged <19 years and at least 85% of provider sites in these jurisdictions participating in their respective IIS. These sites transmit quarterly batches of deidentified IIS records to the CDC to enable public health studies. Data submissions are processed through the IIS Trends in Immunization Practices System, a SAS-based (version 9.3, SAS Institute, Cary, North Carolina) program that performs data quality processing functions, including removing suspected duplicate records 13 and conducting data cleaning to remove records with errors in critical date fields or product identifiers.
Each IIS sentinel site queried its respective IIS during January 2015 and transmitted the deidentified vaccination records to the CDC. We analyzed routinely recommended vaccines given to persons aged <18 years between January 1, 2014, and December 31, 2014. We used reported "CVX codes" to identify the type of vaccine that was administered. These numerical identifiers are defined by the CDC and are used by IIS and other information systems to identify the vaccines indicated for protection against the same disease and have the same formulation, concentration, and manufacturing process. Vaccines that share these aspects receive the same CVX code, even if trade names or manufacturers differ. CVX codes were grouped according to their indication for total counts of vaccines given for each disease, 14 and related CVX codes (eg, preservative-containing and preservative-free influenza vaccines that are reported as distinct CVX codes) are described as a single product type for instances in which age recommendations were identical for the grouped products.
To minimize the effects of misreporting, wherein the vaccine type reported differed from the vaccine type administered, we restricted the analysis to doses that were "verified." We verified doses by comparing the reported lot number to reference tables that linked known lot numbers of publicly purchased vaccines to corresponding CVX codes; this table contained all lot numbers for vaccines purchased or distributed through the CDC's centralized distribution system from July 2013 through December 2014 (personal communication with J. Santoli and L. Galloway, November 17, 2015) . For instances where it was necessary to distinguish between products that shared a CVX code, we identified products by examining reported trade name and manufacturer codes.
Statistical Analyses
We performed all analyses using SAS version 9.3 and Excel 2010 (Microsoft, Redmond, Washington). For each vaccine type within a routinely recommended vaccine type grouping, we quantified doses administered outside the vaccine type's recommended ages, as defined by the "preferable vaccine type begin/end age," identified in Clinical Decision Support for Immunizations (CDSi) version 3.1, 15 with the exception of products for which recommendations changed between 2014 and the release of CDSi version 3.1. CDSi resources systematically document ACIP recommendations; where ACIP recommendations were not available, these tables rely on product labeling for determining recommended ages. Counts of doses outside recommended age limits were included regardless of dose number or intervals between doses. Narrative description of individual products was limited to vaccines with at least 100 doses administered outside recommended age limits; products with fewer errors were included in the tables. We were unable to exclude vaccinations deliberately administered offschedule from dose counts, because the submitted data did not include information describing patient travel, local outbreaks, or other indications of deliberate off-label administration. Underlying health conditions and other indicators of increased risk were not available for individual vaccination records, which prevented allowances for recommendations specific to these groups. For doses administered from multidose vials, we were unable to determine dose volume, and in such instances, dose volumes were assumed to be correct for the patient's age.
Revaccination cost (c) was calculated as c = n (p + a + w + t), where n is the number of verified doses requiring revaccination, p is the price per dose for vaccines purchased through 2014 CDC vaccine contracts, 16 a is administrative cost per vaccination for vaccines administered at a public clinic (set to $8.34
Volume 193 • February 2018 per dose), w is cost for caregiver time (set to $18.48 per hour for 2 hours of time taken off from work), and t is transit cost for commuting to the provider's office (set to $23.84). For instances where multiple formulations or products were grouped, prices were averaged. Costs for vaccine administration, transportation costs, and caregiver time were based on previous reports and adjusted to 2014 dollars using general and medical Consumer Price Indices. 17 
Results
Among the 6 IIS sentinel sites, a total of 13 701 588 doses were reportedly administered to persons aged <18 years during 2014. The number of doses reported per site ranged from 341 160 in North Dakota to 4 007 973 in New York City. Among all 13 701 588 vaccination records, 8 106 501 (59.2%) included lot numbers that were appropriate for the reported vaccine type (CVX code) and thus, were deemed "verified" ( Table I) . We were unable to verify most doses purchased with private funds, because our reference database (containing known lot numbervaccine type pairings) was populated from ordering systems for publicly funded vaccines. Within all verified doses, 7 957 387 (98.2%) were reported by the provider organization where the vaccine was administered, 147 247 (1.8%) were reported by another party as a historical record, and 1867 (>0.1%) were missing data in the field used to indicate the reporting entity (data not shown).
We analyzed childhood and lifespan vaccines to determine how often they were administered after each product's respective maximum recommended age. We identified 3 394 047 verified doses with a maximum age recommendation. Among these doses, 9755 (0.3%) were given after the maximum age ( Table II) . The vaccine most frequently administered after the recommended maximum age was PCV 13 (Prevnar-13; Pfizer, Inc., Philadelphia, PA), for which 1717 doses were administered at age ≥5 years, accounting for 0.2% of 765 618 verified PCV 13 doses in our analysis (Table II) . We identified that 1344 (0.7%) of 194 934 pediatric (0.25-mL) doses of Fluzone Quadrivalent were administered to persons aged ≥36 months (the 0.25-mL dosage is recommended for persons aged 6-35 months). Unlike other maximum age violations analyzed in this study, this scenario requires revaccination with an ageappropriate product and dose volume; repeating these 1344 doses with a 0.5-mL dose of Fluzone Quadrivalent would cost $111 964, including direct and indirect costs ( Table II) .
We identified a total of 6 243 943 verified doses of childhood and lifespan vaccines with minimum age recommendations. Among these, 8920 (0.1%) were given before the recommended minimum age (Table III) . Collectively, quadrivalent injectable influenza vaccines were the vaccine type most frequently administered before the minimum recommended age. This group includes Flulaval Quadrivalent (ID Biomedical Corporation of Quebec, Quebec City, QC, Canada), Fluzone Quadrivalent, Fluarix Quadrivalent preservative-free (GlaxoSmithKline Biologicals, Dresden, Germany), Fluzone Quadrivalent preservative-free (Sanofi Pasteur Inc., Swiftwater, PA), and Flulaval Quadrivalent preservative-free (ID Biomedical Corporation of Quebec, Quebec City, QC, Canada). Among 526 110 verified doses of quadrivalent injectable influenza vaccines, 3835 (0.7%) 0.5-mL doses were administered before the recommended minimum age of 36 months (Table III) . Doses from multidose vials were excluded from this error count to avoid counting 0.25-mL doses of products that can be appropriately administered at age 6-35 months. Although these 0.5-mL/dose product are not recommended for children aged 6-35 months, inadvertent administration within this age group does not necessitate revaccination. We identified 127 doses of injectable quadrivalent influenza vaccines administered before age 6 months (with a 4-day grace period), an age group for which no influenza vaccines are recommended, necessitating revaccination. Among minimum age violations that necessitated revaccination, the most costly were Havrix (GlaxoSmithKline Biologicals, Rixensart, Belgium) and Vaqta (Merck and Co., Inc., Whitehouse Station, NJ; HepA, pediatric/ adolescent), for which 428 doses (0.1% of 832 386 doses) were administered before age 12 months; the estimated cost of repeating these doses was $39 447. Across the 6 IIS sentinel sites, we estimated the total revaccination cost of the childhood and lifespan vaccines administered before the recommended ages as $142 917.
Among DTaP-containing vaccines, DTaP-IPV (Kinrix) was most frequently administered too early. Among 208 218 DTaP-IPV verified doses, 2509 (1.2%) were administered before the minimum recommended age of 48 months. The minimum †Includes hepatitis A vaccine, hepatitis B vaccine, and combination vaccines containing 1 or both of these components. ‡Includes all vaccines indicated for protection against 1 or more of the following diseases: diphtheria, tetanus, or pertussis. §Includes pneumococcal conjugate vaccines (7-valent and 13-valent) and 23-valent pneumococcal polysaccharide vaccine. ¶Includes varicella vaccine; mumps, measles, rubella, and varicella combination vaccine; and herpes zoster vaccine. **Includes mumps, measles, and rubella vaccine and other vaccines containing 1 or more of these components.
† †Combination vaccines and herpes zoster vaccine count toward more than 1 vaccine group; thus, the total dose count is less than the sum of the individual counts shown here.
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Among the total 1 285 222 verified doses of vaccines indicated for adolescents, 622 (<0.1%) were given before the respective minimum recommended age (Table IV) . Adacel (Sanofi Pasteur Limited, Toronto, Ontario, Canada) and Boostrix (GlaxoSmithKline Biologicals, Rixensart, Belgium; Tdap) were most frequently administered before the recommended minimum age; 391 verified doses (0.1% of 281 224) were administered before age 7 years. Among adolescent vaccines requiring revaccination, the most costly were 170 doses of HPV4 (Gardasil, Merck and Co., Inc., Whitehouse Station, NJ; <0.1% of 637 615 doses) administered before age 9 years. Revaccination for these 170 doses would cost $31 741.
We identified 35 352 instances of adult vaccines administered to persons aged <18 years. However, we were unable to verify these doses, because the lot number database that we used for verification was populated from a system used to order federally purchased childhood vaccines. The adult vaccines most frequently administered to individuals aged <18 years were the adult hepatitis A vaccines Havrix and Vaqta (1.0 mL) (18 232 doses administered to persons aged <18 years) and the adult hepatitis B vaccines Recombivax HB (1-mL adult formulation, Merck and Co., Inc., Whitehouse Station, NJ) and Engerix-B (1-mL adult formulation, GlaxoSmithKline Biologicals, Rixensart, Belgium; 11 754 doses administered to persons aged <18 years) (data not shown).
The frequency of vaccination outside recommended minimum or maximum ages was largely consistent among the sites. For each vaccination scenario examined, the frequencies generally differed by no more than 3 percentage points across the 6 IIS sentinel sites (excluding instances with fewer than 10 reported doses). Exceptions to this were Afluria preservative-free (Seqirus Pty Ltd, Parkville, Victoria, Australia) and Fluarix (GlaxoSmithKline Biologicals, Dresden, Germany), which had more variable rates of administration before their recommended minimum ages. The greatest intersite difference was observed for Fluarix; at 1 site, 594 of 2977 (20%) verified Fluarix doses were administered before age 36 months, compared with the 5 other sites, where the frequency of Fluarix administration before age 36 months ranged from 1% to 6% (data not shown).
Discussion
This study provides a comprehensive analysis of administration of vaccines to children and adolescents at incorrect ages within the 6 IIS sentinel sites. Minimum age recommendations N/A, not applicable. *Michigan, Minnesota, North Dakota, 6 contiguous Oregon counties, Wisconsin, and New York City. †Ages listed describe the upper limit of the recommended age range, eg, a value of "<7 y" indicates that a dose administered on the day a child turns 7 years of age would be counted among the doses given after the maximum age, but a dose given one day prior would be considered to be within the recommended age range. Rotavirus vaccination is recommended through the day a child turns 8 years of age, which is indicated for Rotarix and Rotateq. Administration of listed vaccines after the recommended maximum age does not require revaccination, with the exception of the 0.25-mL dose of Fluzone Quadrivalent after age 2 years. Recommended ages were defined by the "preferable vaccine type begin/end age," identified in CDSi version 3.1, with the exception of products for which recommendations changed between 2014 and the release of CDSi version 3.1. ‡Doses were deemed "verified" if the reported lot number and CVX code were correctly matched, as defined by inventory documents for publicly purchased vaccines. §Revaccination cost (c) was calculated as c = n (p + a + w + t) where n is the number of verified doses requiring revaccination, p is price per dose for vaccines purchased through 2014 CDC vaccine contracts, a is administrative cost per vaccination for vaccines administered at a public clinic (set to $8.34 per dose), w is cost for caregiver time (set to $18.48 per hour for 2 hours of time taken off from work), and t is transit cost for bringing the patient to the provider's office (set to $23.84). For instances where multiple formulations or products were grouped, prices were averaged. ¶At the beginning of the study period, Comvax (HepB-Hib) was recommended before age 5 years for Hib and before age 6 years for HepB. This product was discontinued in the US during the study period. **Defined as CVX code 161, which corresponds to Fluzone Quadrivalent in a 0.25-mL prefilled syringe. Administration of this product at age ≥36 months requires revaccination with an ageappropriate product and dose volume. Price listings for Fluzone Quadrivalent (0.5 mL) were used for revaccination costs.
have been established for most vaccines, and maximum age recommendations exist for some. Among vaccines with a maximum age recommendation, fewer than 1 in 300 doses were administered after the recommended age and overall, administration before the recommended minimum ages was even more rare. However, several individual vaccines had much more frequent instances of early administration, and given the large numbers of doses administered, even a small percentage of errors can result in a substantial number of clinical occurrences. The highest rate of minimum age errors was observed among Hiberix (GlaxoSmithKline Biologicals, Rixensart, Belgium), with 68.6% of verified doses given before age 12 †A 4-day grace period was applied to recommended minimum ages, and revaccination is required except where otherwise noted. Recommended ages were defined by the "preferable vaccine type begin/end age," identified in CDSi version 3.1, with the exception of products for which recommendations changed subsequent between 2014 and the release of CDSi version 3.1. ‡Doses were deemed "verified" if the reported lot number and CVX code were correctly matched, as defined by inventory documents for publicly purchased vaccines. §Revaccination cost (c) was calculated as c = n (p + a + w + t), where n is the number of verified doses requiring revaccination, p is price per dose for vaccines purchased through 2014 CDC vaccine contracts, a is administrative cost per vaccination for vaccines administered at a public clinic (set to $8.34 per dose), w is cost for caregiver time (set to $18.48 per hour for 2 hours of time taken off from work), and t is transit cost for bringing the patient to the provider's office (set to $23.84). For instances where multiple formulations or products were grouped, prices were averaged. ¶A 4-day grace period was applied. Administration before 4 days before age 6 weeks is not considered valid for immunity, with the exception of the hepatitis B component. Revaccination is required for the other vaccine components. **A 4-day grace period was not applied to the recommended minimum age. Administration can be valid when administered to younger ages under certain circumstances. † †MMR doses are analyzed at 2 minimum age thresholds: 12 months and 6 months. The ACIP recommends that persons aged ≥12 months receive 2 doses of MMR vaccine separated by at least 28 days, and doses administered before 4 days before the child's first birthday should be repeated after the child's first birthday. In addition, the ACIP recommends that infants aged 6-11 months should receive 1 dose of MMR if they will be traveling internationally, with 2 additional doses administered after age 12 months. Due to the recommendation for MMR vaccination among traveling infants, some doses given before age 12 months should not be counted as errors, and thus, revaccination costs are not included for the "<12 months" age grouping, and these doses are excluded from error count totals. ‡ ‡On January 14, 2016, the minimum recommended age for Hiberix was changed from 12 months to 6 weeks. § §Although the package insert indicates Afluria for persons aged ≥5 years, the ACIP did not recommend use in persons aged <9 years during the study period. ¶ ¶Doses administered from multidose vials of Fluzone Quadrivalent were excluded from counts of doses incorrectly given to persons aged <36 months, because 0.25-mL doses of this product are licensed for persons aged 6-35 months. The administered dose volume was not included in this study, and is assumed to be consistent with product indications.
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Haemophilus influenzae type b can be administered to children as young as 6 weeks, potentially contributing to confusion among products. On January 14, 2016, Hiberix was approved by the US Food and Drug Administration for all 3 doses of the primary infant vaccination series; however, Hiberix was only approved and recommended for the booster dose of this series during the time period considered in this study. 18 Other vaccines commonly administered before the minimum recommended age include quadrivalent inactivated influenza vaccines recommended for persons aged ≥36 months; some of these cases might be attributable to confusion with similar influenza vaccines that are recommended for persons as young as 6 months. The vaccines most frequently administered outside the recommended age limit included vaccine-type groupings containing multiple products with varying age recommendations. The seasonal influenza vaccine schedule exemplifies this complexity, with an array of 20 products categorized into 12 product types (12 CVX codes) with 8 distinct minimum recommended ages (some of which depend on the dose volume administered) and 5 varying maximum age recommendations. Notable among these were 1344 verified doses of the 0.25-mL prefilled syringe formulation of quadrivalent inactivated influenza vaccine (Fluzone) administered outside the recommended age range of 6-35 months. We were unable to differentiate between the pediatric (0.25 mL) and full (0.5 mL) volumes for doses administered from multidose vials, because dosage volume data were not available, potentially leading to underestimation of some minimum age violations. In addition, it is possible that some reported doses might include instances in which two 0.25-mL doses of Fluzone Quadrivalent were given during a single clinical encounter to an individual requiring a 0.5-mL dose, although this practice would be off-label. 5 In such circumstances, the algorithms used in our study would have identified the second 0.25-mL dose as a duplicate entry and would have removed it from the dataset, thereby reducing the impact of this possible scenario.
This report identified approximately $291 000 in direct and indirect revaccination costs that would have been incurred had each error been rectified within the 6 IIS sentinel sites during 2014, which likely represents a small percentage of all costs borne to administer the doses examined. Nationally, the annual expense would likely be >10-fold higher, given that 10% of the US population resides within the sentinel site jurisdictions, and that our study was limited to vaccine lots purchased through federal contracts. Actual costs could be lower, because revaccination can occur when patients present for other clinical services. However, our endpoints and revaccination costs focused on the absolute minimum and maximum ages for each vaccine, and other factors can result in a dose being invalidated and the need for revaccination, including intervals between doses and age requirements specified for particular dose numbers within a series.
The complexity of the age and interval recommendations among primary and catch-up series presents a substantial potential for dose invalidation that is not included in our analysis. During 2000 and 2002, an estimated 10%-21% of US children aged 19-35 months received unnecessary vaccinations subsequent to completion of a vaccine series. 19, 20 One study of childhood records surveyed in 2000 estimated that the national cost to repeat a single vaccination for all children aged 19-35 months with an invalid dose would range from $10 million to $18 million. 8 We did not calculate how often revaccination occurred in instances when it was recommended, but such an analysis would be insightful. Integration of clinical decision support for immunizations into immunization information systems and electronic medical record systems offers †A 4-day grace period was applied to recommended minimum ages, and revaccination was required except where indicated otherwise. Recommended ages were defined by the "preferable vaccine type begin/end age," identified in CDSi version 3.1, with the exception of products for which recommendations changed between 2014 and the release of CDSi version 3.1. ‡Doses were deemed "verified" if the reported lot number and CVX code were correctly matched, as defined by inventory documents for publicly purchased vaccines. §Revaccination cost (c) was calculated as c = n (p + a + w + t), where n is the number of verified doses requiring revaccination, p is price per dose for vaccines purchased through 2014 CDC vaccine contracts, a is administrative cost per vaccination for vaccines administered at a public clinic (set to $8.34 per dose), w is cost for caregiver time (set to $18.48 per hour for 2 hours of time taken off from work), and t is transit cost for bringing the patient to the provider's office (set to $23.84). For instances where multiple formulations or products were grouped, prices were averaged. ¶Menveo is routinely recommended for persons aged 11-15 years, and thus, is listed with adolescent vaccines. However, this product is recommended for children aged 2-23 months at increased risk for meningococcal disease. Data identifying the patients at increased risk were unavailable; therefore, only doses administered before age 2 months were determined to be administered before the minimum recommended age. **A 4-day grace period was not applied to the recommended minimum age; product can be valid when administered to younger children under certain circumstances.
a means of preventing, detecting, and correcting vaccination errors, and improved interoperability between these systems directly improves these clinical practices. 21 The 6 sentinel sites contributing data for these analyses can be considered a convenience sample containing 10% of the US population aged birth through 17 years. Although these data were not adjusted to be representative of the entire US population, the examined vaccination rates were largely consistent among sites, suggesting that the observations likely were typical. Furthermore, our focus on doses that were verified based on the reported lot number effectively focused the analysis on publicly purchased doses. Frequency of vaccination outside recommended ages was generally higher when nonverified doses were included, but whether this difference is attributed to misreporting or to different vaccination practices among public and private vaccine providers is unclear.
The Institute of Medicine presented a comprehensive approach to reducing medication errors, with systems-oriented strategies to reduce errors, including designing vaccine names, labels, and packaging to enhance clarity in clinical environments; ensuring availability of pharmaceutical decision support; making relevant information available at the point of care; and reducing reliance on memory. 22 High-functioning immunization information systems support good vaccination practices, and bidirectional information exchange with medical record systems has been shown to increase the administration of age-appropriate vaccinations and decrease overimmunization. 21, 23 Although familiarity with ACIP recommendations should continue to be encouraged, reduction of errors will require the use of clinical tools, particularly during atypical vaccination scenarios, and system-wide redundancies to review the appropriateness of vaccines before administration. Clinical decision support and vaccine forecasting functions are designed to ensure correct application of these recommendations at the point of clinical care. Prevention of the errors identified in this study would require identification of specific products (eg, through scanned barcodes, inventory lot numbers, manual selection, etc), and flagging products that are inappropriate for a given patient. Highfunctioning immunization information systems are capable of preventing some vaccination errors through forecasting correct vaccines, and by flagging invalid vaccinations that require revaccination, which reduces both overimmunization and underimmunization. 20, 21, 23 This analysis used data from IIS sentinel sites that have advanced functionality, and error rates might be higher in other sites where this functionality is less available to providers at the point of clinical care. Among the scenarios examined, we found a very small number of vaccination schedule errors, despite the complexity of the childhood vaccination schedule and sporadic error reports submitted to other passive reporting systems. Maximizing the completeness of IIS data and development of clinical decision support functionality are critical components in supporting providers to optimize the quality of their vaccination services, thereby maximizing vaccination rates among their patients and minimizing the burden of vaccine-preventable diseases. ■
